News
Upgrade of Redbiotec’s operations to biosafety level 2 plus (BSL-2+)
Redbiotec has successfully upgraded its infrastructure adding additional labs to biosafety level 2 plus (BSL-2+). This is an important step for Redbiotec, as our company is now allowed, among others, to make all the needed genetic engineering of our bacteria of interest such as E. coli and Salmonella as well as oncolytic viruses in-house. Together with the ongoing fruitful partnerships with leading research organizations globally, Redbiotec has a strong position in combining microorganims to fight cancer. The main medical application of Redbiotec’s cancer program is to reduce cancer recurrences. Please find more information here.
Cancer Research Expert joining Redbiotec
Redbiotec is pleased to announce the appointment of Prof. Mark Tangney, PhD, MBA, Principal Investigator Cork Cancer Research Centre, Irland, as additional exclusive advisor to Redbiotec. Mark is Vice-President of the Irish Society for Gene and Cell Therapy (ISGCT). As a renowned expert in the development of microbes as therapeutics he is a very valuable collaboration partner for Redbiotec’s current and future work in oncology. In particular, Redbiotec will profit a lot from Mark Tangney’s work on the associations between bacteria and cancer.
Celebrating Redbiotec’s 10th anniversary in Schloss Au
It was a beautiful event on May 6 at Schloss Au. Redbiotec is very proud and honored of the nearly 100 guests attending the anniversary party in the wonderful Schloss Au right next to the Lake of Zurich. We see this as a proof of the continued high interest in Redbiotec and the big commitment. Some impressions:
We would like to thank all our investors, clients, partners, advisors, suppliers for the successful collaboration in the last ten years – and especially acknowledge all our former and current employees!
Ongoing high interest in Redbiotec/ oversubscription of Redbiotec’s latest financing round
Redbiotec’s latest financing round on May 24 2017 was oversubscibed only a few days after emission. The ongoing support by Redbiotec’s investors is an additional proof for Redbiotec’s science and business. With the new funding Redbiotec plans to further optimize its HSV2 vaccine program and to reach a first proof of concept of its COMO program in oncology.
Top innovator joining Redbiotec
Redbiotec is pleased to announce the appointment of Prof. Dr. Yaakov (Kobi) Benenson, Professor of Synthetic Biology at ETH Zurich, to its team. Prof. Benenson is best known for his work on biomolecular computing circuits. MIT Technology Review named him one of the world’s top 100 young innovators in 2004. Prof. Benenson will reinforce Redbiotec’s activities in engineering bacteria for cancer therapies and diagnostics.